PIK5-12d

N/A

Report date: 2023/08/24 17:29:44
NMEFirst In Class

Base Information

Drug NamePIK5-12d
Drug Alias NamePIK5-12d
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of Action1-phosphatidylinositol 3-phosphate 5-kinase degraders
Targets1-phosphatidylinositol 3-phosphate 5-kinase
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A